ARTICLE | Financial News
argenx planning NASDAQ listing
April 24, 2017 10:10 PM UTC
Antibody engineering company argenx N.V. (Euronext:ARGX) filed to raise up to $74.8 million in a public offering of ADSs on NASDAQ underwritten by Cowen, Piper Jaffray, JMP Securities and Wedbush PacGrow.
argenx's lead candidate, ARGX-113, is in separate Phase II trials to treat myasthenia gravis and primary immune thrombocytopenia. The human antibody Fc fragment, which argenx developed using its ABDEG technology, targets the Fc fragment of IgG receptor transporter alpha (FCRN; FCGRT)...
BCIQ Company Profiles